Company Encyclopedia
View More
name
HUIYU PHARMACEUTICAL
688553.SH
Sichuan Huiyu Pharmaceutical Co., Ltd. research and develops, produces, and sells anti-tumor injection in China and internationally. The company offers injection drug products, such as pemetrexed disodium, methrotraxate, docetaxel, azacitidine, oxaliplatin, cyclophosphamide, irinotecan hydrochloride, paclitaxel, bendamustine hydrochloride, decitabine, palonosetron hydrochloride, plerixafor, levetiracetam concentrated solution, amifostine, levofolate calcium, thiotepa, fulvestrant, and milrinone drugs. It also offers moroxydine sodium chloride, fluorouracil, sodium thiosulfate, acetylcysteine, nimodipine, nimodipine, dihydroxypropyltheophylline, cisatracurium besylate, cladribine, sodium carbosulfan, octreotide acetate, mesobamo, doxorubicin, leucovorin calcium, panosetron hydrochloride, famotidine, etoposide, polymyxin B sulfate, melphalan hydrochloride, thiotepa, teicoplanin, epirubicin hydrochloride, methotrexate, gemcitabine hydrochloride, cytarabine, voriconazole, roxatidine acetate hydrochloride, and bortezomib drugs.
3.144 T
688553.SHMarket value -Rank by Market Cap -/-

Financial Score

09/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking116/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE1.24%D
    • Profit Margin4.80%C
    • Gross Margin82.16%A
  • Growth ScoreD
    • Revenue YoY-12.10%E
    • Net Profit YoY-83.02%E
    • Total Assets YoY-3.43%D
    • Net Assets YoY-4.03%D
  • Cash ScoreC
    • Cash Flow Margin2083.89%A
    • OCF YoY-12.10%E
  • Operating ScoreD
    • Turnover0.2D
  • Debt ScoreB
    • Gearing Ratio23.69%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    HUIYU PHARMACEUTICAL: Plans to collaborate with professional institutions to establish a private equity fund, primarily investing in the biomedical field

    HUIYU PHARMACEUTICAL plans to cooperate with professional institutions to establish a private equity fund, investing in the biomedical field, with a focus on key mid-to-late stage clinical projects. The initial scale of the fund is 400 million yuan, with HUIYU PHARMACEUTICAL as a limited partner subscribing 150 million yuan, accounting for 37.5%

    36Kr·
    SH
    688553
    +1.17%
    36Kr·
    SH
    688553
    +1.17%

    HUIYU PHARMACEUTICAL: The company participates in the national centralized drug procurement and intends to be selected

    HUIYU PHARMACEUTICAL announced that its wholly-owned subsidiary Sichuan HUIYU Haiyue Pharmaceutical Technology Co., Ltd. participated in the national centralized drug procurement bidding. According to the announcement, one of the company's products, Mefenamic Acid Injection, is expected to win the bid at a price of 11.59 yuan, with the procurement period lasting until December 31, 2028

    Zhitong·
    SH
    688553
    +1.17%
    Zhitong·
    SH
    688553
    +1.17%

    HUIYU PHARMACEUTICAL: Shareholder Huang Qianyi's shares in the company have been judicially frozen and pending frozen

    HUIYU PHARMACEUTICAL announced that the shares held by shareholder Huang Qianyi have been judicially frozen, totaling 5.7883 million shares, accounting for 21.27% of his shareholding and 1.37% of the company's total share capital. At the same time, Huang Qianyi has also been subject to a pending freeze of 6.0707 million shares, accounting for 22.30% of his shareholding and 1.43% of the company's total share capital. As of October 9, 2025, Huang Qianyi has a total of 27.2194 million shares judicially frozen, accounting for 100% of his shareholding and 6.43% of the company's total share capital; a total of 6.3507 million shares are pending freeze, accounting for 23.33% of his shareholding and 1.50% of the company's total share capital

    Zhitong·
    SH
    688553
    +1.17%
    Zhitong·
    SH
    688553
    +1.17%

    HUIYU PHARMACEUTICAL: Injectable Paclitaxel (Albumin-Bound) Obtains Overseas Listing License

    HUIYU PHARMACEUTICAL announced that its subsidiary Seacross Pharma (Europe) Ltd. has obtained marketing authorization for injectable paclitaxel (albumin-bound) from the regulatory authorities in the Netherlands, Ireland, Finland, and Sweden. The drug is indicated for the treatment of adult patients with metastatic breast cancer, metastatic pancreatic adenocarcinoma, and non-small cell lung cancer

    Zhitong·
    SH
    688553
    +1.17%
    Zhitong·
    SH
    688553
    +1.17%

    HUIYU PHARMACEUTICAL shareholder Wang Xiaopeng plans to reduce his holdings by no more than 3%

    According to the Zhitong Finance APP, HUIYU PHARMACEUTICAL announced that the company's shareholder Ms. Wang Xiaopeng intends to reduce her holdings in the company by a total of no more than 12.708 million shares through centralized bidding and block trading, with the total reduction not exceeding 3% of the company's total shares

    Zhitong·
    SH
    688553
    +1.17%
    Zhitong·
    SH
    688553
    +1.17%
    © 2025 Longbridge｜Disclaimer